Scientist.com and Orphagen Pharmaceuticals have partnered to offer researchers online access to nuclear receptor profiling and screening services. Scientist.com marketplace users can now easily source cell and biochemical assays for 21 different metabolic, steroid, retinoid and orphan nuclear receptors.
“Orphagen is an industry pioneer in orphan nuclear receptor translational research,” said Kevin Lustig, PhD, CEO and Founder of Scientist.com. “Their state-of-the-art receptor screening platform can help researchers uncover novel nuclear receptor ligands or characterize known ones. In addition, Orphagen also has significant experience in defining novel ligand function in preclinical models.”
In addition to playing important roles in human physiology, nuclear receptors are excellent drug targets. Almost 13% of drugs approved for sale in the US target nuclear receptors, representing more than $30 billion in annual sales. The nuclear receptor superfamily includes the well-characterized endocrine receptors, the adopted orphan receptors, for which ligands have recently been identified, and the orphan receptors, for which ligands have not yet been identified. All three receptor subgroups are the subject of research efforts in a variety of human diseases.
“Because of its many pharma and biotech partnerships, Scientist.com is a great way to expose more researchers to our large portfolio of nuclear receptor pharmacology and selectivity profiling services including orphan and adopted orphan receptor assays,” said Scott Thacher, PhD, CEO and Founder of Orphagen Pharmaceuticals. “Researchers can now order standard or custom nuclear receptor assays with a few mouse clicks.”